NCT02566031 - A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients | Biotech Hunter

Enrollment

379

Participants

Timeline

Start Date

March 23, 2013

Primary Completion Date

June 4, 2018

Study Completion Date

June 4, 2018

Conditions

COPD

Interventions

DRUG

Indacaterol and glycopyrronium (QVA149)

Capsules for inhalation delivered via SDDPI

DRUG

Tiotropium

Capsules for inhalation delivered via HandiHaler® device

Trial Locations (24)

Novartis Investigative Site, Anyang-si

Novartis Investigative Site, Suwon

Novartis Investigative Site, Chuncheon

Novartis Investigative Site, Wŏnju

Novartis Investigative Site, Ulsan

Novartis Investigative Site, Gwangju

Novartis Investigative Site, Jeju City

Novartis Investigative Site, Guri-si

Novartis Investigative Site, Seongnam-si